Cited by 274Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationNuclear Receptors and Signaling

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease

Open access

Levivier, M, Przedborski, S, Bencsics, C, Kang, UJ·1995·The Journal of Neuroscience

DOI 10.1523/jneurosci.15-12-07810.1995PMC PMC6577965

Open this paper in CoChat — free account Open PDF

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons of the substantia nigra pars compacta (SNpc). Although various treatments are successfully used to alleviate the symptoms of PD, none of them prevents or halts the neurodegenerative process of the disease. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of proteins, supports the survival and the differentiation of dopaminergic neurons. BDNF also prevents the death of dopaminergic neurons in vitro, which suggests that it may be of possible use in the development of neuroprotective therapies for PD. To determine whether BDNF is neuroprotective for SNpc dopaminergic neurons in the adult brain, we used a rat model of PD in which degeneration of 60-70% of these neurons was induced by an intrastriatal injection of 6-hydroxydopamine (6-OHDA). We report here that intrastriatal grafts of fibroblasts genetically engineered to produce BDNF partially prevent the loss of nerve terminals and completely prevent the loss of cell bodies of the nigrostriatal dopaminergic pathway that is induced by the intrastriatal injection of 6-OHDA. In contrast, the implantation of control fibroblasts that did not produce BDNF failed to protect nerve terminals and cell bodies against 6-OHDA-induced damage. Our observation that grafts of BDNF-producing fibroblasts protect against 6-OHDA-induced degeneration of SNpc dopaminergic neurons in the adult rat brain opens new perspectives for treatments aimed at the prevention of neurodegeneration in PD, using gene therapy and neurotrophic factors such as BDNF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1523/jneurosci.15-12-07810.1995

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Estimation of nuclear population from microtome sections
Abercrombie, M. (1946) · The Anatomical Record · doi:10.1002/ar.1090940210 · Cited by 4,363
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems
Gerfen, C. R., Herkenham, M. A., & Thibault, J. (1987) · Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 804
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Altar, C. A., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 789
Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section
Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y. (1992) · Nature · doi:10.1038/360757a0 · Cited by 706
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3.
Knüsel, B., Winslow, J. W., Rosenthal, A., Burton, L. E., Seid, D. P., Nikolics, K., & Hefti, F. F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.961 · Cited by 601

Show all 25 references

Research works printed but not linked: 1

Jackson-Lewis V, Jakowec M, Burke RE, Przedbroski S (1995) Time course and morphology of dopaminergic neuronal death caused by neurotoxin I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurode- generation, in press.

Sorted by citations

Items 201–274 of 274

Pathogenic role of glial cells in Parkinson's disease
Przedborski, S., & Goldman, J. E. (2003) · Advances in molecular and cell biology · doi:10.1016/s1569-2558(03)31043-4 · Cited by 15
Self-citation
Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus
van Esseveldt, K. E., Liu, R., Hermens, W. T. J. M. C., Verhaagen, J., & Boer, G. J. (1997) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(96)00131-8 · Cited by 15
Long-Term Transgene Expression in Fetal Rat Suprachiasmatic Nucleus Neurografts Followingex VivoAdenoviral Vector-Mediated Gene Transfer
Boer, G. J., van Esseveldt, K. E., Hermens, W. T. J. M. C., Liu, R., & Verhaagen, J. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6489 · Cited by 15
The BDNF-TrkB signaling pathway is partially involved in the neuroprotective effects of hydrogen sulfide in Parkinson's disease
Hacıoğlu, G., Cırrık, S., Yavuz, B. T., Tomruk, C., Keskin, A., Uzunoğlu, E., & Takır, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175595 · Cited by 14
Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice
Makar, T. K., Trisler, D. N., Eglitis, M. A., Mouradian, M. M., & Dhib-Jalbut, S. S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.045 · Cited by 14
Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting
Pawar, G. N., Parayath, N. N., Sharma, A., Coito, C., Khorkova, O., Hsiao, J. H., Curry, W. T., Amiji, M. M., & Bleier, B. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660841 · Cited by 14
Gene therapy in Parkinson?s disease
Eberhardt, O., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0947-x · Cited by 14
Phenotype, Compartmental Organization and Differential Vulnerability of Nigral Dopaminergic Neurons
González‐Hernández, T., Afonso‐Oramas, D., & Cruz‐Muros, I. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_2 · Cited by 13
Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent l-3,4-dihydroxyphenylalanine administration
Lee, W. Y., Lee, E. A., Jeon, M. Y., Kang, H. Y., & Park, Y. G. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.09.012 · Cited by 13
The Use of Neurotoxins to Lesion Catecholamine-Containing Neurons to Model Clinical Disorders
Breese, C. R., & Breese, G. R. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-477-1_2 · Cited by 13
Neurotrophin Strategies for Neuroprotection: Are They Sufficient?
Steiner, J. P., & Nath, A. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9533-5 · Cited by 12
Estrogen Reduces BDNF Level, but Maintains Dopaminergic Cell Density in the Striatum of MPTP Mouse Model
Tripanichkul, W., Gerdprasert, O., & Jaroensuppaperch, E.-O. (2010) · International Journal of Neuroscience · doi:10.3109/00207451003721892 · Cited by 12
An NR2B-Dependent Decrease in the Expression of trkB Receptors Precedes the Disappearance of Dopaminergic Cells in Substantia Nigra in a Rat Model of Presymptomatic Parkinson's Disease
Riquelme, E., Abarca, J., Campusano, J. M., & Bustos, G. A. (2012) · Parkinson s Disease · doi:10.1155/2012/129605 · Cited by 11
Gene therapy for Parkinson’s disease
Le, H., & Frim, D. M. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.2.151 · Cited by 10
A transgenic mouse model engineered to investigate human brain-derived neurotrophic factor in vivo
Guillemot, F., Cerutti, I., Auffray, C., & Devignes, M. (2007) · Transgenic Research · doi:10.1007/s11248-006-9060-0 · Cited by 10
Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson’s disease
Lilli, N. L., Révy, D., Robelet, S., & Lejeune, B. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s202966 · Cited by 10
Elevated biomarkers of neural injury in older adults following head-down bed rest: links to cardio-postural deconditioning with spaceflight and aging
Blaber, A. P., Sadeghian, F., Divsalar, D. N., & Scarisbrick, I. A. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1208273 · Cited by 9
CURRENT CONTROVERSIES AND FUTURE DIRECTIONS IN BASAL GANGLIA RESEARCH
Garcia‐Cairasco, N., Miguel, E. C., Rauch, S. L., & Leckman, J. F. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70354-3 · Cited by 7
NIH 3T3 cells or engineered NIH 3T3 cells stably expressing GDNF can protect primary dopaminergic neurons
Ma, D., Wang, X., & Han, J. (2000) · Neurological Research · doi:10.1080/01616412.2000.11740715 · Cited by 8
New Developments in the Surgery for Parkinson's Disease
Honey, C. R., Gross, R. E., & Lozano, A. M. (1999) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100000093 · Cited by 8
In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification
Ebrahimi, P., Davoudi, E., Sadeghian, R., Zadeh, A. Z., Razmi, E., Heidari, R., Morowvat, M. H., & Sadeghian, I. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03141-4 · Cited by 7
Associations between eight anthropometric indices and Parkinson’s disease: a nationwide population-based study
Hu, W., Zhang, Y., & Liu, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1621658 · Cited by 7
An Overview of Novel Therapies for Parkinson's Disease
Fahn, S. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6382 · Cited by 7
Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice
Halbach, O. V. B. U., & Minichiello, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0498-2 · Cited by 7
Targeted BDNF upregulation via upstream open reading frame disruption
Ning, F., Goedert, T., Svrzikapa, N., Yan, D., Friedrichsen, H. J., Hanson, B., Ljungdahl, A., Dafinca, R., Talbot, K., Sanders, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.024 · Cited by 6
Neuronal chloride transporters in neurodegenerative diseases
Yang, L., & Justice, N. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00023-6 · Cited by 6
Gene Therapy for Parkinson??s Disease
Segovia, J. (2002) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200202020-00006 · Cited by 6
A novel approach to detecting plasma synuclein aggregates for Parkinson’s disease diagnosis
Ko, H. R., Lee, D., Park, H., Jeong, H., Yoon, T., Kang, S., Park, H. L., Kwon, S. J., Kim, S., Ryoo, N., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01083-z · Cited by 5
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates
Singh, A. P., Gutekunst, C., Uthayathas, S., Finberg, J. P. M., Mewes, K., Gross, R. E., Papa, S. M., & Feld, Y. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1559-z · Cited by 5
The change of the neuron–glia differentiation rate in human neural precursor cells (HPCs) and Ad-BDNF-/-GDNF-infected HPCs following the administration of a neurotoxin
Yoo, Y. M., Kim, Y. J., & Lee, U. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.043 · Cited by 5
Gene Transfer for Adult CNS Regeneration and Aging
Senut, M., Aubert, I., Horner, P. J., & Gage, F. H. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-478-8_16 · Cited by 5
Production of functional recombinant tyrosine hydroxylase by the BPV-1 expression plasmids in the cell cultures
Lampela, P., Huotari, M., Harjula, A., Oinonen, L., Ustav, M., Ylä‐Herttuala, S., Männistö, P. T., & Raasmaja, A. (2003) · Plasmid · doi:10.1016/j.plasmid.2003.09.001 · Cited by 4
Neurotrophic factors for the investigation and treatment of movement disorders
de Yébenes, J. G., Sánchez, M. P., & Mena, M. A. (2003) · Neurotoxicity Research · doi:10.1007/bf03033377 · Cited by 4
Somatic gene therapy in animal models of Parkinson’s disease
Bauer, M., Ueffing, M., Meitinger, T., & Gasser, T. (1999) · Springer eBooks · doi:10.1007/978-3-7091-6369-6_12 · Cited by 4
The Dissolution Behavior and Solvent Effect Analysis of Pramipexole in Pure Organic Solvents
Yu, Y. Y., Wu, Y., Liu, K., Guo, Q., Guo, C., Shi, X., & Zhang, S. (2023) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.3c00378 · Cited by 3
Neurotrophic factors and sleep
Mattson, M. P. (2005) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(04)17006-5 · Cited by 3
Molecules for Neuroprotection and Regeneration in Animal Models of Parkinson’s Disease
Ole Isacson, A., Costantini, L. C., & Galpern, W. R. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_11 · Cited by 3
Future Prospects of Gene Therapy for Treating CNS Diseases
Peterson, D. A., Ray, J., & Gage, F. H. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_24 · Cited by 3
Freshwater Clam Extract Mitigates Neuroinflammation and Amplifies Neurotrophic Activity of Glia: Insights from In Vitro Model of Neurodegenerative Pathomechanism
Lin, M.-S., Chen, S., Hua, K., Chen, W., Hsieh, C.-C., & Lin, C.-C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030553 · Cited by 2
Bidirectional Relationship between the BDNF Gene and miRNA: Implications for PD Pathogenesis
Elangovan, A., Iyer, M., HariKrishnaReddy, D., Wander, A., Kinoshita, M., Krishnan, J., & Vellingiri, B. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00173 · Cited by 4
Gene Transfer into the Central and Peripheral Nervous System: Applications for the Treatment of Neurodegenerative Diseases and Peripheral Neuropathies
Pradat, P., & Mallet, J. J. (2003) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2003.10648037 · Cited by 2
14-3-3ζ protein protects against brain ischemia/reperfusion injury and induces BDNF transcription after MCAO in rat
Khalesi, N., Bandehpour, M., Bigdeli, M. R., Niknejad, H., Dabbagh, A., & Kazemi, B. (2019) · Journal of Applied Biomedicine · doi:10.32725/jab.2019.007 · Cited by 2
Cellular Delivery of Neurotrophic Factors as a Potential Treatment for Huntington's Disease
Emerich, D. F., Kordower, J. H., & Ole Isacson, A. (1999) · Elsevier eBooks · doi:10.1016/b978-012705070-6/50019-6 · Cited by 2
Trasplante de células naturales ‘dopaminotróficas’: nuevo concepto terapéutico antiparkinsoniano
Fernández‐Espejo, E., Banoua, F. E., Ramos, I. C., Galán-Rodríguez, B., & Cordero, J. A. F. (2003) · Revista de Neurología · doi:10.33588/rn.3606.2002588 · Cited by 2
Encapsulated Cell Implants as a Novel Treatment for Parkinson's Disease
Tseng, J., & Aebischer, P. (2003) · Humana Press eBooks · doi:10.1385/1-59259-142-6:279 · Cited by 2
Delivery of transgenically modified adult bone marrow cells to the rodent central nervous system
Dhib-Jalbut, S. S., & Mouradian, M. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.5.669 · Cited by 2
Neuroprotective activity of Hibiscus abelmoschus Linn. against 6-OHDA induced Parkinson’s disease in rats
Akki, K., Shalavadi, M. H., Chandrashekhar, V. M., Teli, S., Anawal, L., & Khombare, B. (2024) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2024.100027 · Cited by 1
Involvement of neurotrophins in the pathogenesis of Parkinson's disease
Povarnina, P. Y., Гудашева, Т. А., & Львович, Д. В. (2026) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2025-4-9-16 · Cited by 1
Role of Exercise and GDNF in an Animal Model of Parkinson's Disease: Implications for Neuroprotection
Cohen, A. D. (2006) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Introduction to Regenerative Medicine
Ambrosio, F., Trumbower, R. D., Wolf, S., & Wagner, W. (2014) · Orthopaedic Section, APTA, Inc. eBooks · doi:10.17832/isc.2014.23.2.1 · Cited by 1
Epigenomics of neurological disorders
Khorkova, O., Hsiao, J. H., & Wahlestedt, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00003-9 · Cited by 1
Approaches in the treatment of Parkinson's disease : a focus on stem cell-based therapies.
Al-Maqtari, T. (2012) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/34 · Cited by 1
Brain-derived neurotrophic factor bound with lecithin derivative showed a markedly enhanced pharmacological potency due to its potent cell membrane affinity followed by prolonged MAPK activation
Igarashi, R., Nakayama, T., Takenaga, M., Ichinohe, M., Yamaguchi, Y., Matsumoto, K., Kitagawa, A., Nakamura, N., Kawai, S., Nakagawa, T., et al. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.027 · Cited by 1
GENE DELIVERY TO THE LUNG BY MEANS OF SYNGENEIC FIBROBLASTS: AN EXPERIMENTAL MODEL
Suda, A., Takiguchi, Y., Omori, S., Miyazawa, H., Sugimoto, T., Kurosu, K., Tatsumi, K., Tanabe, N., Kuriyama, T., Hiroshima, K., et al. (2003) · Experimental Lung Research · doi:10.1080/01902140303781 · Cited by 1
Stimulation of neurotrophin synthesis by 4-methylcatechol: a promising approach for neuroprotection
Furukawa, S., Nitta, A., & Furukawa, Y. (1999) · Biomedical Reviews · doi:10.14748/bmr.v10.7 · Cited by 1
Ex Vivo Gene Therapy in the Central Nervous System
Blesch, A., & Tuszynski, M. H. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_11 · Cited by 1
Gene therapy for Parkinson’s disease: review and update
Kang, U. J., & Frim, D. M. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1551 · Cited by 1
Self-citation
Strategies for Administering Neurotrophic Factors to the Central Nervous System
Hottinger, A. F., & Aebischer, P. (1999) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-59920-0_10 · Cited by 1
Intrastriatal Injections of Quinolinic Acid as a Model for Developing Neuroprotective Strategies in Huntington’s Disease
Emerich, D. F. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_15 · Cited by 1
Einfluss des GDNF-Rezeptors RET auf die akute MPTP-Toxizität in der Maus
Kowsky, S. (2011) · doi:10.53846/goediss-1073
Molecular and Cellular Characterization of Dopamine Neuron Stimulating Peptides
Kelps, K. A. (2013) · UKnowledge (University of Kentucky)
Chapter 3.2.1 Gene transfer and therapy in the CNS
Senut, M., Suhr, S. T., & Gage, F. H. (1999) · Techniques in the behavioral and neural sciences · doi:10.1016/s0921-0709(99)80033-9
DERIVATION, ENRICHMENT AND CHARACTERIZATION OF DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS
Schwartz, C. M. (2010) · Figshare
Maladies neurodégénératives : thérapie génique
y Ribotta, M. G., & Privat, A. (2000) · Annales de l Institut Pasteur / Actualités · doi:10.1016/s0924-4204(00)80012-8
Maladies neurodégénératives : thérapie génique
y Ribotta, M. G., & Privat, A. (1997) · Journal of Engineering and Technology Management · doi:10.1016/s0923-4748(97)80012-4
Novel neurotrophic treatments in rats and toxin sensitivity of genetically modified mice in the unilateral 6 OHDA model of Parkinson's disease
Piltonen, M. (2012) · Työväentutkimus Vuosikirja
Cell-Based Replacement Therapies for Parkinson’s Disease
Fernández‐Espejo, E., & Liste, I. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-252-0_24
Future Surgical Therapies in Parkinson's Disease
Kang, U. J., Papasian, N., Chang, J. W., & Lee, W. Y. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-312-5_23
Self-citation
Controlling Transgene Expression in the Central Nervous System For MRI-Guided Focused Ultrasound Delivery of Adeno-Associated Virus
Weber‐Adrian, D. (2017) · TSpace (University of Toronto)
Neurotrophic Factors
Hagg, T. (1998) · CRC Press eBooks · doi:10.1201/9781420048544.ch9
mGluR5 Modulation as a Treatment for Parkinson’s Disease
Farmer, K. (2018) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2018-14442
The Role of Brain Derived Neurotrophic Factor (BDNF) in Regulating α-synuclein Pathology in Primary Microglia and Neurons.
Paquette, C. (2023) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2023-15633
Plasticité GABAergique et épilepsie : focus sur le proBDNF
Riffault, B. (2016) · theses.fr (ABES) · doi:10.70675/aebe024bzc909z4a8azaf3az2554d9189e99
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation
Maini, R., Tamada, K., Fukuda, K., Takumi, T., & Suga, H. (2026) · ChemBioChem · doi:10.1002/cbic.70517

Authors: Levivier, M., Przedborski, S., Bencsics, C., & Kang, U.
Affiliations: Columbia University (US)
ORCID: Levivier, M
Przedborski, S
Venue: The Journal of Neuroscience
Publisher: Society for Neuroscience
Published: 1995-12-01
Volume: 15
Issue: 12
Pages: 7810-7820
ISSN: 0270-6474 (ISSN-L)
1529-2401
DOI: 10.1523/jneurosci.15-12-07810.1995
PMC: PMC6577965
OpenAlex: W1590012920
Cited by: 274
References: 25
Citations by year: 2026: 2 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 5 · 2018: 9 · 2017: 3 · 2016: 9 · 2015: 11 · 2014: 11 · 2013: 8 · 2012: 9
FWCI: 7.32
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-sa
creativecommons.org/licenses/by-nc-sa/4.0/ (vor, 183 d)
Locations: Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Irving A. Hansen Memorial Foundation
National Institutes of Health (5r29ns032080-05, 5k08ns001724-03)
Parkinsonfonden
Fogarty International Center
National Institute of Neurological Disorders and Stroke (1-K08-NS01724-01, R29 NS32080)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, brain-derived neurotrophic factor, dopaminergic neuron loss, substantia nigra pars compacta, 6-hydroxydopamine, gene therapy, neuroprotection, nigrostriatal pathway, neurotrophic factors
MeSH terms: Animals, Autoradiography, Corpus Striatum, Dopamine, Fibroblasts, Genetic Engineering, Male, Nerve Degeneration, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Rats, Inbred F344, Oxidopamine, Brain-Derived Neurotrophic Factor, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks